coagulation factor X
Target not currently curated in GtoImmuPdb
Target id: 2359
Nomenclature: coagulation factor X
Family: S1: Chymotrypsin
Annotation status:
Annotated and expert reviewed. Please contact us if you can help with updates.
» Email us
Contents:
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 488 | 13q34 | F10 | coagulation factor X | |
| Mouse | - | 493 | 8 A1.1 | F10 | coagulation factor X | |
| Rat | - | 482 | 16q12.5 | F10 | coagulation factor X | |
| Previous and Unofficial Names |
| Cf10 | coagulation factor 10 | fX | stuart factor |
| Database Links |
|
| Specialist databases | |
| MEROPS | S01.216 (Hs) |
| Other databases | |
| BRENDA | 3.4.21.6 |
| CATH/Gene3D | 4.10.740.10 |
| ChEMBL Target | CHEMBL244 (Hs), CHEMBL3755 (Rn) |
| DrugBank Target | P00742 (Hs) |
| Ensembl Gene | ENSG00000126218 (Hs), ENSMUSG00000031444 (Mm), ENSRNOG00000033444 (Rn) |
| Entrez Gene | 2159 (Hs), 14058 (Mm), 29243 (Rn) |
| Human Protein Atlas | ENSG00000126218 (Hs) |
| KEGG Enzyme | 3.4.21.6 |
| KEGG Gene | hsa:2159 (Hs), mmu:14058 (Mm), rno:29243 (Rn) |
| OMIM | 613872 (Hs) |
| Orphanet | ORPHA121658 (Hs) |
| RefSeq Nucleotide | NM_000504 (Hs), NM_007972 (Mm), NM_017143 (Rn) |
| RefSeq Protein | NP_000495 (Hs), NP_031998 (Mm), NP_058839 (Rn) |
| SynPHARM |
78505 (in complex with apixaban) 80504 (in complex with eribaxaban) 78509 (in complex with rivaroxaban) |
| UniProtKB | P00742 (Hs), O88947 (Mm), Q63207 (Rn) |
| Wikipedia | F10 (Hs) |
| Enzyme Reaction |
||||
|
||||
Download all structure-activity data for this target as a CSV file 
| Inhibitors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||
|
||||||||||||
| General Comments |
| A plasma-derived blood coagulation factor X concentrate called Coagadex® has been approved by both the European Medicines Agency and the US FDA as the first treatment for hereditary factor X deficiency. Coagadex® can be used to treat bleeding episodes and to manage perioperative care in adults and children >12 years old. |
References
1. Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A, Kawabe Y, Igawa T, Tsunoda H, Nogami K et al.. (2017) Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb. Haemost., 117 (7): 1348-1357. [PMID:28451690]
2. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. (2010) Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol., 30 (3): 376-81. [PMID:20139357]
3. Pinto DJ, Smallheer JM, Cheney DL, Knabb RM, Wexler RR. (2010) Factor Xa inhibitors: next-generation antithrombotic agents. J. Med. Chem., 53 (17): 6243-74. [PMID:20503967]
4. Qiu X, Zhou J, Wang W, Zhao Z, Tang L, Sun S. (2019) Effect of a new inhibitor of factor Xa zifaxaban, on thrombosis in the inferior vena cava in rabbits. J. Thromb. Thrombolysis, 47 (1): 80-86. [PMID:30298304]
5. Van Huis CA, Casimiro-Garcia A, Bigge CF, Cody WL, Dudley DA, Filipski KJ, Heemstra RJ, Kohrt JT, Leadley Jr RJ, Narasimhan LS et al.. (2009) Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action. Bioorg. Med. Chem., 17 (6): 2501-11. [PMID:19231206]
6. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM. (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost., 6 (5): 820-9. [PMID:18315548]
7. Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T et al.. (2009) Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg. Med. Chem. Lett., 19 (8): 2179-85. [PMID:19297154]
How to cite this page
S1: Chymotrypsin: coagulation factor X. Last modified on 24/01/2019. Accessed on 17/06/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359.
